Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease

NCT02035982 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease
Dementia

Interventions

DRUG: Cholinesterase Inhibitor
DRUG: Placebo

Sponsor

Sunnybrook Health Sciences Centre